Advertisement
Singapore markets close in 7 hours 43 minutes

  • Straits Times Index

    3,281.01
    -6.74 (-0.20%)
     

  • Nikkei

    37,617.00
    -11.48 (-0.03%)
     

  • Hang Seng

    17,284.54
    0.00 (0.00%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    63,986.70
    -533.08 (-0.83%)
     

  • CMC Crypto 200

    1,388.69
    +6.12 (+0.44%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,340.00
    -2.50 (-0.11%)
     

  • Crude Oil

    83.88
    +0.31 (+0.37%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,567.58
    -1.67 (-0.11%)
     

  • Jakarta Composite Index

    7,155.29
    -7,174.53 (-50.07%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Company News for Oct 11, 2021

Zacks Equity Research
·1-min read

  • Share of Accolade, Inc. ACCD gained 4.3% after the company reported second quarter fiscal 2021 loss of $0.43 per share, lower than the Zacks Consensus Estimate of a loss of $0.45.

  • ChemoCentryx, Inc.’s CCXI shares surged 96% after the company announced that the Food and Drug Administration has given approval to its Anca-associated vasculitis therapy.

  • Shares of Allogene Therapeutics, Inc. ALLO plummeted 46.1% after the Food and Drug Administration put a hold on its cancer drug trials after chromosomal abnormality was detected in a single patient.

  • Shares of Walmart, Inc. WMT advanced 0.3% after the retailer announced it holiday season plans that include the launch of a direct-to-home wine delivery service.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Walmart Inc. (WMT) : Free Stock Analysis Report
 
ChemoCentryx, Inc. (CCXI) : Free Stock Analysis Report
 
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
 
Accolade, Inc. (ACCD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research